Peptibase
Weight Loss

Semaglutide

Also known as: Ozempic, Wegovy, Rybelsus

FDA Approved
Share:

Key Facts: Semaglutide

Category
Weight Loss
FDA Status
FDA Approved
Clinical Status
FDA Approved - T2D, weight loss, CV risk, CKD/kidney protection (Jan 2025); Oral Wegovy approved Dec 2025; Wegovy HD 7.2mg injection approved March 2026 (20.7% mean weight loss)
Administration
Subcutaneous injection weekly, or oral (Rybelsus)
Typical Dose
1-2.4 mg weekly (after titration)
Frequency
Once weekly
Duration
Long-term / chronic use
Also Known As
Ozempic, Wegovy, Rybelsus

Mechanism of Action

Semaglutide mimics the GLP-1 hormone, slowing gastric emptying, increasing insulin secretion, reducing glucagon release, and acting on brain appetite centers to reduce hunger and increase satiety. It has 94% amino acid similarity to human GLP-1.

Research Summary

STEP trials: 15-17% weight loss. FLOW trial: 24% reduction in kidney disease progression (Jan 2025 approval). Wegovy pill: 16.6% weight loss (Dec 2025 approval). Oral Rybelsus approved for CV risk reduction (Oct 2025). In January 2025, Ozempic received FDA approval for reducing kidney disease progression in T2D patients with CKD. In March 2026, Wegovy HD (7.2mg) was approved, delivering 20.7% mean weight loss — the highest for any injectable semaglutide dose.

Trial Progress:FDA Approved
Pre
I
II
III
IV
FDA

FDA Approval Studies

This peptide is FDA approved. Below are the key clinical trials that supported its approval.

STEP Program (Semaglutide Treatment Effect in People with obesity)

Novo Nordisk • Phase 3

Approved 2021
Participants:

4,500+ participants across STEP 1-4 trials

Duration:

68 weeks

Primary Endpoint:

Percent change in body weight from baseline

Key Results:
  • ✓STEP 1: 14.9% average weight loss vs 2.4% placebo
  • ✓STEP 2 (with diabetes): 9.6% weight loss vs 3.4% placebo
  • ✓STEP 3 (with lifestyle intervention): 16.0% weight loss
  • ✓STEP 4: Continued treatment maintained weight loss vs regain with placebo
View Study

SUSTAIN Program (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes)

Novo Nordisk • Phase 3

Approved 2017
Participants:

8,000+ participants across SUSTAIN 1-10 trials

Duration:

30-104 weeks

Primary Endpoint:

HbA1c reduction from baseline

Key Results:
  • ✓Superior HbA1c reduction vs comparators (sitagliptin, exenatide, dulaglutide)
  • ✓Significant cardiovascular benefit shown in SUSTAIN-6
  • ✓26% reduction in major cardiovascular events
  • ✓Consistent weight loss of 4-6 kg across trials
View Study

Dosing Information

FDA Approved·Human clinical trials completed, FDA approved

Typical Dosingⓘ

Community experience

Common Dose

1-2.4 mg weekly (after titration)

Range

0.25-2.4 mg weekly

Frequency

Once weekly

Titrate up slowly over 16-20 weeks to minimize GI side effects. Start at 0.25 mg, increase every 4 weeks. Many stay at 1 mg if tolerating well.

Research Dosingⓘ

Scientific studies

Prescribed doses per FDA labeling

Duration

Long-term / chronic use

Administration

Subcutaneous injection weekly, or oral (Rybelsus)

Timing & Administration

Best Time to Take

Morning, same day each week

Once weekly, same day and time

Food Recommendation

With or without food

Why This Timing?

Weekly injection should be at a consistent time. Morning allows monitoring for any side effects during waking hours.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

  • ●Nausea (common, usually transient)
  • ●Vomiting
  • ●Diarrhea
  • ●Constipation
  • ●Abdominal pain
  • ●Headache
  • ●Fatigue
  • ●Injection site reactions
  • ●Hypoglycemia (with insulin/sulfonylureas)
  • ●Gallbladder problems
  • ●Pancreatitis
  • ●Acute kidney injury
  • ●BOXED WARNING: Thyroid C-cell tumors - contraindicated with MTC/MEN 2

References

Research This Peptide Further

PubMedClinicalTrials.govFDA.gov

Frequently Asked Questions

What does Semaglutide do?

A GLP-1 receptor agonist with multiple FDA approvals including weight loss, T2D, CV risk reduction, and kidney protection. Wegovy pill approved Dec 2025 as first oral GLP-1 for weight loss.

How does Semaglutide work?

Semaglutide mimics the GLP-1 hormone, slowing gastric emptying, increasing insulin secretion, reducing glucagon release, and acting on brain appetite centers to reduce hunger and increase satiety. It has 94% amino acid similarity to human GLP-1.

Is Semaglutide FDA approved?

Yes, Semaglutide is FDA approved. FDA Approved - T2D, weight loss, CV risk, CKD/kidney protection (Jan 2025); Oral Wegovy approved Dec 2025; Wegovy HD 7.2mg injection approved March 2026 (20.7% mean weight loss)

What are the side effects of Semaglutide?

Reported side effects include: Nausea (common, usually transient), Vomiting, Diarrhea, Constipation, Abdominal pain. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Semaglutide?

Community-reported common dose: 1-2.4 mg weekly (after titration) (Once weekly). Range: 0.25-2.4 mg weekly. Administration: Subcutaneous injection weekly, or oral (Rybelsus). FDA-approved medication. Follow prescriber guidance.

Related Peptides

Peptides commonly compared with Semaglutide or used in similar applications.

Tirzepatide

FDA

A dual GIP/GLP-1 receptor agonist representing the next generation of incretin-based therapies. Shows superior weight loss compared to semaglutide in head-to-head trials. First medication approved for obstructive sleep apnea.

Weight Loss

Retatrutide

Clinical Trials

A triple agonist targeting GLP-1, GIP, and glucagon receptors. Phase 3 trials show up to 28.7% weight loss (71 lbs average), the highest of any obesity drug. Expected FDA approval late 2026 to early 2027.

Weight Loss

AOD-9604

Clinical Trials

A modified fragment of human growth hormone (amino acids 177-191) studied for fat metabolism effects without the broader hormonal effects of full GH.

Weight Loss

Liraglutide

FDA

An FDA-approved GLP-1 receptor agonist for type 2 diabetes and chronic weight management. The predecessor to semaglutide with daily dosing.

Weight Loss

Cagrilintide

Clinical Trials

A long-acting amylin analog developed by Novo Nordisk for obesity treatment. Works through a different mechanism than GLP-1 agonists, targeting amylin receptors in the brain to reduce appetite and slow gastric emptying. Shows enhanced weight loss when combined with semaglutide (CagriSema).

Weight Loss

Orforglipron

FDA

An oral non-peptide GLP-1 receptor agonist. NDA under FDA review with decision expected April 10, 2026. If approved, will compete directly with oral Wegovy.

Weight Loss
How to Use SemaglutideSemaglutide AlternativesCompare with SimilarBrowse All Peptides

Want updates on Semaglutide research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides